Stereotaxis wins FDA clearance for GenesisX, a streamlined robotic system aimed at boosting hospital adoption and accelerating growth.
Stereotaxis, Inc. ( STXS ) Q3 2025 Earnings Call November 11, 2025 4:30 PM EST Company Participants David Fischel - CEO & Chairman Kimberly Peery - Chief Financial Officer Conference Call Participants Joshua Jennings - TD Cowen, Research Division Adam Maeder - Piper Sandler & Co., Research Division Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Presentation Operator Good afternoon. Thank you for joining us for Stereotaxis' Third Quarter 2025 Earnings Conference Call.
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.08 per share a year ago.
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | David Leo Fischel C.A.I.A., CEO | AMEX Exchange | 85916J409 CUSIP |
| US Country | 139 Employees | - Last Dividend | 4 Nov 2013 Last Split | 12 Aug 2004 IPO Date |
Stereotaxis, Inc. is a pioneering company in the field of robotic systems, specializing in the design, manufacture, and marketing of advanced robotics, instruments, and information systems geared towards the interventional laboratory sector. Operating both in the United States and internationally, the company's cutting-edge technology primarily serves the purpose of enhancing the precision and safety of complex interventional procedures. Through its innovative solutions, Stereotaxis aims to facilitate physicians in navigating and manipulating devices within the human body with an unprecedented level of control and accuracy. Founded in 1990 and headquartered in Saint Louis, Missouri, Stereotaxis has established a strong reputation for its contribution to minimally invasive medical procedures, particularly in the realm of cardiology. The company’s commitment to innovation is also reflected in its strategic collaborations, such as with MAGiC catheter for cardiac ablation procedures, further emphasizing its role in advancing medical technology.